Highlights
• BLTE stock rose on December 01, 2025, after new clinical data.
• Tinlarebant met the primary endpoint in a phase 3 Stargardt disease trial.
• Company expects to submit New Drug Applications in the first half of next year.

Belite Bio (NASDAQ:BLTE) moved higher on December 01, 2025, even as broader market sentiment remained subdued. The clinical-stage biotechnology company reported new findings from its late-stage trial for tinlarebant, its leading oral therapy candidate for retinal disorders. The stock closed the session with a 12% gain after the company detailed progress in its phase 3 study.

Phase 3 Trial Delivers Positive Readout

Belite announced that tinlarebant met its primary endpoint in a phase 3 trial evaluating the treatment in adolescents diagnosed with Stargardt disease. The rare genetic condition can lead to progressive loss of central vision, making lesion growth reduction an important indicator of treatment benefit.

According to the update, tinlarebant achieved a nearly 36% reduction in lesion growth compared with placebo. Belite also noted minimal change in visual acuity over a 24-month period, which it described as a meaningful finding in the context of disease progression.

The company highlighted the significance of the data and included a statement from CEO Tom Lin in its disclosure. He said, “Not only was tinlarebant shown to be efficacious in slowing retinal degeneration, but this is also the first time that an oral treatment was able to demonstrate a clinically meaningful outcome in retinal degenerative disease.”

Next Steps for Tinlarebant

With the phase 3 trial meeting its primary endpoint, Belite outlined its regulatory plans. The company said it expects to submit New Drug Applications for tinlarebant in the first half of next year. The timeline places the programme on track for further review as the company continues to develop treatments targeting retinal health.

Belite’s update arrived during a session where many stocks traded lower. The company’s announcement stood out due to the clear milestone in a late-stage clinical study. Market reaction on December 01, 2025, reflected the attention given to developments in late-stage drug pipelines, particularly in areas addressing conditions with limited treatment options.

The focus now shifts to regulatory submission preparations and potential next stages for tinlarebant as Belite continues to advance its clinical programmes.